Breaking News Instant updates and real-time market news.

CNAT

Conatus

$1.96

-0.04 (-2.00%)

18:29
10/03/16
10/03
18:29
10/03/16
18:29

Conatus up 8.7% after Emricasan abstracts accepted for AASLD annual meeting

CNAT Conatus
$1.96

-0.04 (-2.00%)

05/09/16
BMUR
05/09/16
NO CHANGE
Target $7
BMUR
Buy
Conatus price target lowered to $7 from $13 at Brean Capital
Brean Capital lowered its price target on Conatus to $7 from $13 as the firm believes data from its Phase ll liver cirrhosis study has yielded inconclusive results. Brean Capital lowered its price target based on cutting the probability of success for emricasan in liver cirrhosis to 20% from 30%. Brean Capital maintained its Buy rating on Conatus shares, as they believe the company remains on the forefront of developing liver disease treatments.
07/01/16
ROTH
07/01/16
INITIATION
Target $4
ROTH
Buy
Conatus coverage resumed with a Buy at Roth Capital
Roth Capital analyst Sa'ar Yaniv resumed coverage of Conatus with a Buy rating and $4 price target.
08/29/16
HCWC
08/29/16
NO CHANGE
Target $15
HCWC
Buy
Conatus drug further validated by collaboration, says H.C. Wainwright
H.C. Wainwright analyst Ed Arce keeps a Buy rating on Conatus Pharmaceuticals following the company's collaboration agreement with Exalenz Biosciences. The analyst remains positive on Conatus's prospects in non-alcoholic steatohepatitis cirrhosis. The collaboration brings the use of Exalenz's BreathID Methacetin Breath Test to monitor patients in the upcoming Phase 2b trial evaluating the safety and efficacy of emricasan in 160 patients with liver cirrhosis associated with NASH and severe portal hypertension, Arce tells investors in a research note. Using a "simple and non-invasive test provides not only further scientific validation of emricasan for the treatment of NASH cirrhosis, but it also serves as the first non-invasive test that can assist clinicians to conveniently and cost-effectively monitor the effect of the drug at the point of care," the analyst writes. He has a Buy rating on Conatus with a $15 price target.
09/20/16
STFL
09/20/16
NO CHANGE
Target $6
STFL
Buy
Stifel says Conatus emricasan an interesting asset amid increased focus on NASH
Following Allergan's (AGN) acquisition of small-cap NASH play Tobira (TBRA), Stifel analyst Stephen Willey notes there are some "interesting" similarities between Conatus (CNAT) and the latter. However, the analyst points out that the clearest distinctions between the two are Conatus' emphasis on some of the downstream consequences of NASH fibrosis and the amount of meaningful clinical data generated to date. Willey still thinks Conatus' emricasan is an interesting asset, but urges investors seeking Tobira-like premiums to exercise a level of caution. He reiterates a Buy rating and $6 price target on Conatus' shares. In afternoon trading, shares of Conatus have gained about 20% to $2.10.

TODAY'S FREE FLY STORIES

AMZN

Amazon.com

$740.34

-3.31 (-0.45%)

11:32
12/05/16
12/05
11:32
12/05/16
11:32
Hot Stocks
Amazon confirms Amazon Go 'store with no checkout required' »

Amazon announces Amazon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KNX

Knight Transportation

$36.45

0.45 (1.25%)

11:31
12/05/16
12/05
11:31
12/05/16
11:31
Conference/Events
Knight Transportation management to meet with Stephens »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBR

Nabors Industries

$17.50

0.445 (2.61%)

11:30
12/05/16
12/05
11:30
12/05/16
11:30
Options
Calendar spreads in Nabors trading with hefty markup »

Calendar spreads in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:30
12/05/16
12/05
11:30
12/05/16
11:30
General news
Treasury Futures Action: a large block purchase of Ultra bonds »

Treasury Futures Action:…

ABMD

Abiomed

$108.87

1.48 (1.38%)

11:26
12/05/16
12/05
11:26
12/05/16
11:26
Conference/Events
Abiomed management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

DISCA

Discovery

$26.60

-0.55 (-2.03%)

11:25
12/05/16
12/05
11:25
12/05/16
11:25
Hot Stocks
Breaking Hot Stocks news story on Discovery »

Discovery up nearly 3% as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

SUM

Summit Materials

$23.46

0.2 (0.86%)

11:20
12/05/16
12/05
11:20
12/05/16
11:20
Conference/Events
Summit Materials management to meet with Stephens »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Dec

P

Pandora

$13.59

0.255 (1.91%)

11:20
12/05/16
12/05
11:20
12/05/16
11:20
Options
Bullish option play opened in Pandora »

Bullish option play…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DISCA

Discovery

$26.60

-0.55 (-2.03%)

, T

AT&T

$38.75

0.14 (0.36%)

11:18
12/05/16
12/05
11:18
12/05/16
11:18
Hot Stocks
Discovery CEO says 'well positioned' to take product direct to consumer in 2017 »

Discovery (DISCA) says…

DISCA

Discovery

$26.60

-0.55 (-2.03%)

T

AT&T

$38.75

0.14 (0.36%)

TWX

Time Warner

$93.84

0.04 (0.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

  • 07

    Dec

  • 07

    Dec

SCG

SCANA

$70.63

-0.29 (-0.41%)

11:18
12/05/16
12/05
11:18
12/05/16
11:18
Hot Stocks
SCANA, Westinghouse receive order from DRB about construction milestone payment »

South Carolina Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BGNE

BeiGene

$30.86

0.06 (0.19%)

11:18
12/05/16
12/05
11:18
12/05/16
11:18
Hot Stocks
BeiGene: BGB-3111 'highly active' in CLL/SLL, well tolerated in Phase 1 study »

BeiGene presented updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

NKE

Nike

$51.77

1.31 (2.60%)

11:16
12/05/16
12/05
11:16
12/05/16
11:16
Technical Analysis
Nike moves to monthly highs, levels to watch »

The stock is up over 3%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Dec

TGTX

TG Therapeutics

$5.50

0.05 (0.92%)

11:16
12/05/16
12/05
11:16
12/05/16
11:16
Hot Stocks
TG Therapeutics announces oral data presentation for TGR-1202 at ASH »

TG Therapeutics announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

$NYE

NYSE Market Internals

11:16
12/05/16
12/05
11:16
12/05/16
11:16
Technical Analysis
NYSE market internals summary »

Breadth is bullish across…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

11:16
12/05/16
12/05
11:16
12/05/16
11:16
Technical Analysis
NASDAQ market internals summary »

Volume is very light for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NYT

New York Times

$13.00

0.2 (1.56%)

11:15
12/05/16
12/05
11:15
12/05/16
11:15
Periodicals
New York Times sees more-than-tenfold increase in daily subs, Politico reports »

The New York Times has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

11:15
12/05/16
12/05
11:15
12/05/16
11:15
General news
Breaking General news story  »

6-Month Bill Auction to…

11:15
12/05/16
12/05
11:15
12/05/16
11:15
General news
Breaking General news story  »

3-Month Bill Auction to…

GWPH

GW Pharmaceuticals

$112.32

3.04 (2.78%)

11:14
12/05/16
12/05
11:14
12/05/16
11:14
Recommendations
GW Pharmaceuticals analyst commentary  »

GW Pharmaceuticals price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Dec

ORA

Ormat Technologies

$47.50

0.17 (0.36%)

11:14
12/05/16
12/05
11:14
12/05/16
11:14
Conference/Events
Ormat Technologies management to meet with Oppenheimer »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 13

    Dec

FGP

Ferrellgas Partners LP

$6.20

0.55 (9.73%)

11:13
12/05/16
12/05
11:13
12/05/16
11:13
Upgrade
Ferrellgas Partners LP rating change  »

Ferrellgas Partners LP…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

ULTA

Ulta Beauty

$253.39

-4.02 (-1.56%)

11:12
12/05/16
12/05
11:12
12/05/16
11:12
Conference/Events
Ulta Beauty management to meet with Oppenheimer »

Field trip to company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 13

    Dec

RSX

Market Vectors Russia ETF

$20.25

0.41 (2.07%)

11:10
12/05/16
12/05
11:10
12/05/16
11:10
Options
Bullish option action in the VanEck Vectors Russia Fund »

Bullish option action in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:10
12/05/16
12/05
11:10
12/05/16
11:10
General news
Treasury announced a $45 B 4-week bill sale for Tuesday »

Treasury announced a $45…

CDK

CDK Global

$56.91

-0.24 (-0.42%)

11:07
12/05/16
12/05
11:07
12/05/16
11:07
Conference/Events
CDK Global management to meet with Oppenheimer »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.